... In March 2026, the FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. ...
... In March 2026, the FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. ...